These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 33723354)

  • 1. Homozygous variant in MADD, encoding a Rab guanine nucleotide exchange factor, results in pleiotropic effects and a multisystemic disorder.
    Abu-Libdeh B; Mor-Shaked H; Atawna AA; Gillis D; Halstuk O; Shaul-Lotan N; Slae M; Sultan M; Meiner V; Elpeleg O; Harel T
    Eur J Hum Genet; 2021 Jun; 29(6):977-987. PubMed ID: 33723354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MADD/DENN/Rab3GEP functions as a guanine nucleotide exchange factor for Rab27 during granule exocytosis of rat parotid acinar cells.
    Imai A; Ishida M; Fukuda M; Nashida T; Shimomura H
    Arch Biochem Biophys; 2013 Aug; 536(1):31-7. PubMed ID: 23702376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GDP/GTP exchange factor MADD drives activation and recruitment of secretory Rab GTPases to Weibel-Palade bodies.
    Kat M; Bürgisser PE; Janssen H; De Cuyper IM; Conte IL; Hume AN; Carter T; Voorberg J; Margadant C; Bierings R
    Blood Adv; 2021 Dec; 5(23):5116-5127. PubMed ID: 34551092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder.
    Schneeberger PE; Kortüm F; Korenke GC; Alawi M; Santer R; Woidy M; Buhas D; Fox S; Juusola J; Alfadhel M; Webb BD; Coci EG; Abou Jamra R; Siekmeyer M; Biskup S; Heller C; Maier EM; Javaher-Haghighi P; Bedeschi MF; Ajmone PF; Iascone M; Peeters H; Ballon K; Jaeken J; Rodríguez Alonso A; Palomares-Bralo M; Santos-Simarro F; Meuwissen MEC; Beysen D; Kooy RF; Houlden H; Murphy D; Doosti M; Karimiani EG; Mojarrad M; Maroofian R; Noskova L; Kmoch S; Honzik T; Cope H; Sanchez-Valle A; ; Gelb BD; Kurth I; Hempel M; Kutsche K
    Brain; 2020 Aug; 143(8):2437-2453. PubMed ID: 32761064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights into the clinical and molecular spectrum of the MADD-related neurodevelopmental disorder.
    Abdel-Salam GMH; Abdel-Hamid MS
    J Hum Genet; 2024 Jun; 69(6):263-270. PubMed ID: 38459224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment.
    Kurada BRVVSN; Li LC; Mulherkar N; Subramanian M; Prasad KV; Prabhakar BS
    J Biol Chem; 2009 May; 284(20):13533-13541. PubMed ID: 19289468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, biochemical, and genetic spectrum of MADD in a South African cohort: an ICGNMD study.
    Bisschoff M; Smuts I; Dercksen M; Schoonen M; Vorster BC; van der Watt G; Spencer C; Naidu K; Henning F; Meldau S; McFarland R; Taylor RW; Patel K; Fassad MR; Vandrovcova J; ; Wanders RJA; van der Westhuizen FH
    Orphanet J Rare Dis; 2024 Jan; 19(1):15. PubMed ID: 38221620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calloso-adreno-scrotal agenesis associated with biallelic MAPK-activating death domain protein (MADD) variant: Further phenotypic delineation of MADD deficiency.
    Darouich S; Darouich S
    Am J Med Genet A; 2024 Mar; 194(3):e63463. PubMed ID: 37932938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand-resistant thyroid cancer cells makes them susceptible to treatment with this ligand.
    Li LC; Jayarama S; Pilli T; Qian L; Pacini F; Prabhakar BS
    Thyroid; 2013 Jan; 23(1):70-8. PubMed ID: 22998497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MADD is a downstream target of PTEN in triggering apoptosis.
    Jayarama S; Li LC; Ganesh L; Mardi D; Kanteti P; Hay N; Li P; Prabhakar BS
    J Cell Biochem; 2014 Feb; 115(2):261-70. PubMed ID: 24038283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the MYBPC1 phenotypic spectrum: a novel homozygous mutation causes arthrogryposis multiplex congenita.
    Ekhilevitch N; Kurolap A; Oz-Levi D; Mory A; Hershkovitz T; Ast G; Mandel H; Baris HN
    Clin Genet; 2016 Jul; 90(1):84-9. PubMed ID: 26661508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MADD regulates natural killer cell degranulation through Rab27a activation.
    Medlyn MJ; Maeder E; Bradley C; Phatarpekar P; Ham H; Billadeau DD
    J Cell Sci; 2024 Apr; 137(7):. PubMed ID: 38506245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IG20/MADD plays a critical role in glucose-induced insulin secretion.
    Li LC; Wang Y; Carr R; Haddad CS; Li Z; Qian L; Oberholzer J; Maker AV; Wang Q; Prabhakar BS
    Diabetes; 2014 May; 63(5):1612-23. PubMed ID: 24379354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL suppresses human breast cancer cell migration via MADD/CXCR7.
    Wang R; Li JC
    Asian Pac J Cancer Prev; 2015; 16(7):2751-6. PubMed ID: 25854358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells.
    Mulherkar N; Prasad KV; Prabhakar BS
    J Biol Chem; 2007 Apr; 282(16):11715-21. PubMed ID: 17314102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biallelic Loss of Proprioception-Related PIEZO2 Causes Muscular Atrophy with Perinatal Respiratory Distress, Arthrogryposis, and Scoliosis.
    Delle Vedove A; Storbeck M; Heller R; Hölker I; Hebbar M; Shukla A; Magnusson O; Cirak S; Girisha KM; O'Driscoll M; Loeys B; Wirth B
    Am J Hum Genet; 2016 Nov; 99(5):1206-1216. PubMed ID: 27843126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIF1Bbeta- and KIF1A-mediated axonal transport of presynaptic regulator Rab3 occurs in a GTP-dependent manner through DENN/MADD.
    Niwa S; Tanaka Y; Hirokawa N
    Nat Cell Biol; 2008 Nov; 10(11):1269-79. PubMed ID: 18849981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
    Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS
    Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MADD Expression in Lung Adenocarcinoma and its Impact on Proliferation and Apoptosis of Lung Adenocarcinoma Cells.
    Ye B; Zhong F; Yu G; Lou H; Hu J
    Comb Chem High Throughput Screen; 2019; 22(3):207-215. PubMed ID: 30947659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of MADD in lung adenocarcinoma tissues and its effects on proliferation and apoptosis of lung adenocarcinoma A549 cells].
    Wei YP; Wu JX; Guo YF; Sun GY; Zhang Q; Bi WX; Dong L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Apr; 28(4):354-7. PubMed ID: 22482404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.